Indivior (INDV): Assessing Valuation After Strong SUBLOCADE Growth, Raised Guidance and Newtyn’s Big Bet

Simply Wall St.12-11

Newtyn Management’s decision to boost its stake in Indivior (INDV) and make it the fund’s largest holding came right as the company reported a 15% jump in SUBLOCADE sales and raised full year guidance...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590633775?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2025-12-11 09:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590633775","market":"nz","top_or_hot":-1,"title":"Indivior (INDV): Assessing Valuation After Strong SUBLOCADE Growth, Raised Guidance and Newtyn’s Big Bet","media":"Simply Wall St.","content":"<div>\n<p>Newtyn Management’s decision to boost its stake in Indivior (INDV) and make it the fund’s largest holding came right as the company reported a 15% jump in SUBLOCADE sales and raised full year guidance...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/indivior-indv-assessing-valuation-after-strong-sublocade-gro\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Indivior (INDV): Assessing Valuation After Strong SUBLOCADE Growth, Raised Guidance and Newtyn’s Big Bet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndivior (INDV): Assessing Valuation After Strong SUBLOCADE Growth, Raised Guidance and Newtyn’s Big Bet\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-11 09:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/indivior-indv-assessing-valuation-after-strong-sublocade-gro><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Newtyn Management’s decision to boost its stake in Indivior (INDV) and make it the fund’s largest holding came right as the company reported a 15% jump in SUBLOCADE sales and raised full year guidance...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/indivior-indv-assessing-valuation-after-strong-sublocade-gro\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INDV","symbol_name":"INDIVIOR PLC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/indivior-indv-assessing-valuation-after-strong-sublocade-gro","article_id":"2590633775","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior/news/indivior-indv-assessing-valuation-after-strong-sublocade-gro","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2590633775","pubTimestamp":1765416509,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Newtyn Management’s decision to boost its stake in Indivior (INDV) and make it the fund’s largest holding came right as the company reported a 15% jump in SUBLOCADE sales and raised full year guidance.\nSee our latest analysis for Indivior.\nInvestors have been quick to price in that stronger SUBLOCADE trajectory and cost reset, with the share price delivering a 30 day return of 14.8 percent and a powerful year to date share price return of 183.6 percent. This reinforces a clear, momentum...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"INDV":"INDIVIOR PLC","BK4007":"制药","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"Indivior(INDV)：在SUBLOCADE强劲增长、上调指引和Newtyn的大赌注后评估估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INDV":1.5,"DCF":1},"content_text":"Newtyn Management’s decision to boost its stake in Indivior (INDV) and make it the fund’s largest holding came right as the company reported a 15% jump in SUBLOCADE sales and raised full year guidance. See our latest analysis for Indivior. Investors have been quick to price in that stronger SUBLOCADE trajectory and cost reset, with the share price delivering a 30 day return of 14.8 percent and a powerful year to date share price return of 183.6 percent. This reinforces a clear, momentum driven rerating on top of a three year total shareholder return of 61.1 percent and a five year total shareholder return of 416 percent. If Indivior’s surge has you rethinking what momentum looks like in healthcare, it could be a good moment to explore other healthcare stocks that are starting to gain attention. With earnings surging, guidance raised, and the share price already more than doubling this year, are investors still looking at an undervalued turnaround story, or is Indivior now fully pricing in its next leg of growth? AdvertisementPrice to Earnings of 35.7x: Is it justified? Indivior’s last close at $35.45 comes with a rich 35.7x price to earnings multiple, signaling the market is paying up for its earnings compared to peers. The price to earnings ratio measures how much investors are willing to pay today for each dollar of current earnings, a key yardstick for profitable pharmaceutical businesses. For Indivior, the current 35.7x multiple is well above both the company’s estimated fair price to earnings ratio of 27.9x and the peer group average of 27.1x, implying investors are already baking in strong profit growth. That premium suggests the market may be overestimating what today’s earnings are worth, especially when judged against the SWS fair ratio level the multiple could gravitate toward over time. With Indivior trading at 35.7x, versus a 27.9x fair ratio and a 19.2x US pharmaceuticals industry average, the stock screens as materially more expensive than both its model based fair value benchmark and sector, underlining how stretched the valuation looks on this metric. Explore the SWS fair ratio for Indivior Result: Price to earnings of 35.7x (OVERVALUED) However, legal setbacks or slower than expected SUBLOCADE uptake could quickly compress Indivior’s premium multiple and challenge the current momentum narrative. Find out about the key risks to this Indivior narrative. Another View on Value While the price to earnings ratio points to an expensive stock, the SWS DCF model paints a very different picture, suggesting Indivior is trading about 66.6 percent below its estimated fair value of $106.15. If that discount is even roughly right, is the market still underestimating the turnaround? Look into how the SWS DCF model arrives at its fair value. INDV Discounted Cash Flow as at Dec 2025Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Indivior for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 905 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Indivior Narrative If you see the story playing out differently, or simply want to dig into the numbers yourself, you can build a custom view in just a few minutes. Do it your way. A great starting point for your Indivior research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision. Ready for more investment ideas? Before momentum moves on without you, use the Simply Wall Street Screener to uncover fresh opportunities that match your strategy, risk appetite, and return goals.  Capture early stage potential by targeting cash generative small caps using these 3598 penny stocks with strong financials that already show real business traction, not just speculation. Position yourself at the front of technological change with these 26 AI penny stocks, where scalable software models and data moats can compound value for years. Lock in attractive entry points through these 905 undervalued stocks based on cash flows that trade below their cash flow potential, giving you a margin of safety as sentiment shifts.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590633775","isCrawlerRequest":true}